RN1201 / AlloRunning Therapeutics - LARVOL DELTA

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P1 trial • Immunology

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies (clinicaltrials.gov) - P1 | N=27 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma (clinicaltrials.gov) - P1 | N=19 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology

An Exploratory Clinical Study on the Safety and Efficacy of RN1201 Injection as First-line Treatment for Newly Diagnosed Multiple Myeloma (ChiCTR) - P1 | N=9 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Soochow University, Suzhou, China; The First Affiliated Hospital of Soochow University, Suzhou, China

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology